Kodiak Sciences (KOD) Enterprise Value (2018 - 2026)
Kodiak Sciences' (KOD) quarterly Enterprise Value came in at -$169.5 million in Q1 2026, down 22.09% YoY from -$217.6 million in Q1 2025, and up 19.22% on a QoQ basis from -$209.9 million in Q4 2025.
Analysis
Kodiak Sciences (KOD) Enterprise Value (2018 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 10 years of Enterprise Value data on file, last reported at -$169.5 million in Q1 2026.
- Quarterly Enterprise Value fell 22.09% year-over-year to -$169.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$169.5 million (down 22.09% YoY) and the FY2025 annual result came in at -$209.9 million, down 24.86% from the prior year.
- Enterprise Value improved to -$169.5 million in Q1 2026, from -$209.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$72.0 million in Q3 2025 to a low of -$671.7 million in Q1 2022.
- A 5-year average of -$308.8 million and a median of -$245.9 million in 2024 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 63.59% in 2025, down 24.86% in 2025.
- Tracing KOD's Enterprise Value over 5 years: stood at -$485.3 million in 2022, then surged by 41.16% to -$285.5 million in 2023, then soared by 41.13% to -$168.1 million in 2024, then decreased by 24.86% to -$209.9 million in 2025, then advanced by 19.22% to -$169.5 million in 2026.
- The last three Enterprise Value figures came in at -$169.5 million (Q1 2026), -$209.9 million (Q4 2025), and -$72.0 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Kodiak Sciences | 2.21 Bn | 2.21 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.32 Bn |
| Mar 31, 2026 | 2.20 Bn |
| Dec 31, 2025 | 1.52 Bn |
| Sep 30, 2025 | 795.55 Mn |
| Jun 30, 2025 | 92.86 Mn |
| Mar 31, 2025 | 9.38 Mn |
| Dec 31, 2024 | 356.56 Mn |
| Sep 30, 2024 | -60.52 Mn |
| Jun 30, 2024 | -95.58 Mn |
| Mar 31, 2024 | 30.35 Mn |
| Dec 31, 2023 | -125.88 Mn |
| Sep 30, 2023 | -251.23 Mn |
| Jun 30, 2023 | -16.74 Mn |
| Mar 31, 2023 | -96.65 Mn |
| Dec 31, 2022 | -110.55 Mn |
| Sep 30, 2022 | -132.56 Mn |
| Jun 30, 2022 | -200.41 Mn |
| Mar 31, 2022 | -270.75 Mn |
| Dec 31, 2021 | 3.66 Bn |
| Sep 30, 2021 | 4.16 Bn |